{"id":"W2905172465","doi":"10.3747/co.25.4287","title":"Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort","year":2018,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Cegep de Saint Jerome; Regional Municipality of Durham; Royal Columbian Hospital; Dr. Georges-L.-Dumont University Hospital Centre; McGill University Health Centre; Juravinski Cancer Centre","funders":"Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Cohort; Lung cancer; Internal medicine; Clinical trial; Randomized controlled trial; Cancer; Oncology; Demographics; Immunotherapy; Demography","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001533505,0.0004121432,0.0005619641,0.0005482503,0.00192225,0.001098043,0.0006595345,0.0005296655,0.001671941],"category_scores_gemma":[0.003527305,0.00017447,0.0007604053,0.001420742,0.0007025242,0.0003095516,0.0005150244,0.000849705,0.0001827076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02142703,"about_ca_system_score_gemma":0.02316017,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8595347,"about_ca_topic_score_gemma":0.9076154,"domain_scores_codex":[0.9988312,0.0001852157,0.00005427175,0.0002471131,0.0003596246,0.0003226031],"domain_scores_gemma":[0.9976809,0.0002326394,0.000713436,0.0001512117,0.0006220347,0.0005996643],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006197562,0.0003324042,0.9679903,0.0001514326,0.0007084875,0.0003636437,0.000473065,0.001157564,0.001094436,0.0004488093,0.005826124,0.01525619],"study_design_scores_gemma":[0.0009128838,0.001127028,0.9879981,0.00005190538,0.0005452116,0.0005273487,0.0005652446,0.001561575,0.0004993413,0.0001702094,0.005961948,0.00007912588],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917905,0.000757708,0.0001278987,0.0005613066,0.00001931771,0.0001173751,0.004775128,0.0000123822,0.001838325],"genre_scores_gemma":[0.9966409,0.000315842,0.0002376609,0.0002108832,0.00002303043,0.00005008906,0.002289517,0.000005513158,0.0002266243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1404653,"threshold_uncertainty_score":0.282585,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04051589643830278,"score_gpt":0.3768204557669513,"score_spread":0.3363045593286486,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}